Key result
In a review of 164 trials of self-management interventions, 60% excluded patients with multimorbidity and only 35% reported on multimorbidity in their patient samples.
Systematic Review (n=164)
Trials of self-management interventions frequently exclude patients with multimorbidity and poorly report its presence, limiting the external validity of trial evidence for clinical populations.
May limit applicability of self-management results to multimorbid patients in practice; challenges generalizability of current trial evidence.
Background Multimorbidity has many potential implications for healthcare delivery, but a particularly important impact concerns the validity of trial evidence underpinning clinical guidelines for individual conditions. Objective To review how authors of published trials of self-management interventions reported inclusion criteria, sample descriptions, and consideration of the impact of multimorbidity on trial outcomes. Methods We restricted our analysis to a small number of exemplar long-term conditions: type 2 diabetes mellitus, coronary heart disease, and chronic obstructive pulmonary disease. We focussed our search on published Cochrane reviews. Data were extracted from the trials on inclusion/exclusion, sample description, and impact on outcomes. Results Eleven reviews consisting of 164 unique trials were identified. Sixty percent of trials reported excluding patients with forms of multimorbidity. Reasons for exclusion were poorly described or defined. Reporting of multimorbidity within the trials was poor, with only 35% of trials reporting on multimorbidity in their patient samples. Secondary analyses, exploring the impact of multimorbidity, were very rare. Conclusions The importance of multimorbidity in trials is only going to become more important over time, but trials often exclude patients with multimorbidity, and reporting of multimorbidity in trials including such patients is generally poor. This limits judgements about the external validity of the results for clinical populations. A consistent approach to the conduct and reporting of secondary analyses of the effects of multimorbidity on outcomes, using current best-practice guidance, could lead to a rapid development of the evidence base.
No takes yet. Share an insight, caveat, or question.
Kenning et al. (2014) conducted a systematic review in Long-term conditions (type 2 diabetes mellitus, coronary heart disease, chronic obstructive pulmonary disease) (n=164). Self-management interventions was evaluated on Reporting of multimorbidity exclusion. In a review of 164 trials of self-management interventions, 60% excluded patients with multimorbidity and only 35% reported on multimorbidity in their patient samples.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: